Olaris, Inc. Announces Presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Olaris, Inc.  is pleased to announce that the company’s presentation on the identification of metabolic reprograming associated with CDK4/6 sensitivity and resistance has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research (AACR) annual meeting, to be held April 8th - 13th.


The presentation, led by Olaris Metabolite Scientist Dr. Chandrashekhar Honrao, will describe the recent results of a collaboration between Olaris and the Dana Farber Cancer Institute. Using a human breast cancer cell line model and isotope tracers, researchers determined that glucose metabolism was altered following treatment with two CDK4/6 inhibitors, palbociclib and abemaciclib. They also found that cells resistant to the drugs had alterations in different metabolic pathways, representing the first-ever evidence of metabolite signatures specific to two different CDK4/6 inhibitors.


View the presentation at https://youtu.be/nXBiGRcnqXk.

April 8, 2022

Olaris, Inc. Announces Presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting